CN1695731A - Preparation of Chinese traditional medicine for treating trmor in alimentary canal - Google Patents
Preparation of Chinese traditional medicine for treating trmor in alimentary canal Download PDFInfo
- Publication number
- CN1695731A CN1695731A CN 200510025151 CN200510025151A CN1695731A CN 1695731 A CN1695731 A CN 1695731A CN 200510025151 CN200510025151 CN 200510025151 CN 200510025151 A CN200510025151 A CN 200510025151A CN 1695731 A CN1695731 A CN 1695731A
- Authority
- CN
- China
- Prior art keywords
- group
- treatment
- zhijing
- keli
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 238000002360 preparation method Methods 0.000 title claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 78
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 29
- 241001038563 Pseudostellaria Species 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 82
- 239000008187 granular material Substances 0.000 claims description 8
- 240000008397 Ganoderma lucidum Species 0.000 claims description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000005903 Dioscorea Nutrition 0.000 claims description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 2
- 235000004879 dioscorea Nutrition 0.000 claims description 2
- 241000234273 Dioscorea Species 0.000 claims 1
- 241000222336 Ganoderma Species 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 description 38
- 230000000694 effects Effects 0.000 description 34
- 229940079593 drug Drugs 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 24
- 206010017758 gastric cancer Diseases 0.000 description 22
- 208000005718 Stomach Neoplasms Diseases 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- 201000011549 stomach cancer Diseases 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 229930192392 Mitomycin Natural products 0.000 description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 10
- 229960004857 mitomycin Drugs 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 230000000973 chemotherapeutic effect Effects 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229920001231 Polysaccharide peptide Polymers 0.000 description 8
- 229960004397 cyclophosphamide Drugs 0.000 description 8
- 108010022457 polysaccharide peptide Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 7
- 206010000087 Abdominal pain upper Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 6
- GTBYFJITPRWOBT-UHFFFAOYSA-N diethyl 1,4-dihydroxynaphthalene-2,3-dicarboxylate Chemical compound C1=CC=C2C(O)=C(C(=O)OCC)C(C(=O)OCC)=C(O)C2=C1 GTBYFJITPRWOBT-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 201000005619 esophageal carcinoma Diseases 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 238000002575 gastroscopy Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- -1 50ulConA Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004229 gastric stump Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Abstract
A Chinese medicine for treating the tumor in digestive tract is proportionally prepared from 8 Chinese-medicinal materials including pseudostellaria root, Chinese angelica root, ganoderma, yam, etc.
Description
Technical field
The present invention relates to Chinese patent medicine preparation, especially about a kind of Chinese medicine preparation for the treatment of digestive tract tumor.
Background technology
Tumor is a kind of disease of serious threat human health.Along with human diet structure's change and various factors influence, the incidence rate of tumor is progressively soaring, especially with digestive tract tumor's sickness rate for the highest.According to statistics, Asia digestive tract tumor sickness rate accounts for more than 60% of whole tumors.Digestive tract tumor refers to occur in the tumor at esophagus, stomach, duodenum, jejunum, ileum, colon, rectum position, as the esophageal carcinoma, gastric cancer, rectal cancer etc.Wherein gastric cancer is modal malignant tumor of digestive tract, add up according to data at home and abroad, gastric cancer accounts for 50%～60% of digestive tract tumor, about 70% patient betides 40～60 years old, and the women is more, and mortality rate also occupies position first of the various cancers, according to western countries' survey data, the late gastric cancer five year survival rate only accounts for 5%～10%, and row occupy cancerous protuberance reason the 5th to the 7th, the serious harm people's life and health.China also is the country occurred frequently of gastric cancer in the world, and the gastric cancer case in the whole world about 35% occurs in China.The patient that China dies from gastric cancer every year surpasses 260,000, accounts for 1/5 of whole tumor mortality.China's gastric cancer mortality in 2000 is 24.65/10 ten thousand according to estimates, and the male is 32.23/10 ten thousand, and the women is 16.54/10 ten thousand, occupies first of man, the women malignant tumor death respectively.Esophageal carcinoma also is one of common malignancy, China die from every year this disease have 150,000 approximately surplus the people, be more common in 50-70 year, men and women's morbidity ratio is about 8: 1, its morbidity is complicated, and is how relevant with dietary structure.Intestinal cancer also is one of multiple digestive tract tumor, mostly occurs after 40 years old, has the patient's carcinoma more than 60% to occur in rectum approximately.The early-stage cancer patient tends to the surgical radical treatment excision, but in, patients with terminal surgery alone treatment often can not effect a radical cure, many employing therapeutic modalities that postoperative is put, chemotherapy combines, and fecund is given birth to the side reaction syndrome in the general chemicotherapy: weak as body, show as general fatigue, disease such as have palpitation, breathe hard more; Gastricism, common loss of appetite, the diseases such as diarrhoea of retching of feeling sick; Bone marrow depression mostly is leukopenia and thrombocytopenia.At this situation, this disease clinical research and medicine tackling key problem have been carried out, made a kind of Chinese patent medicine of new treatment digestive tract tumor, by the therapy of combining Chinese and Western medicine tumor, not only the infantile tumour patient had antitumous effect, alleviate the toxicity of cancer patient in chemicotherapy but also have, improve patient's life quality.
Summary of the invention
The invention provides a kind of Chinese medicine preparation (having another name called ZHIJING KELI) for the treatment of digestive tract tumor, this Chinese medicine preparation is according to traditional differentiation of tcm, in conjunction with the experience that sums up in the practice of distinguished veteran doctors of TCM long term medical, utilization modern pharmaceutical technology is processed into a kind ofly has a spleen invigorating kidney, the replenishing essence marrow, replenishing QI and blood, the new drug of the treatment digestive tract tumor of clear stagnant heat effect, this medicine is to treat first or all suitable use of other treatment means nonresponder to various digestive tract tumor, particularly better to the gastric cancer effect, digestive tract tumor is put, chemotherapy adverse effect all has good result.
The cause of disease of digestive tract tumor is comparatively complicated.The traditional Chinese medical science thinks that the principal element of gastrointestinal tumor morbidity is an intemperance of taking food, is worried excessively, and spleen injury is due to depressed expectorant coagulates.Though motherland's medical science does not have digestive tract tumor's name of disease,, " gathering ", “ mass in the abdomen that belong in conjunction with symptom analysis more ", " stomachache " category, patients with terminal operation afterwards chemicotherapy person belongs to " asthenia " category more.In, late gastric cancer patient, especially behind chemicotherapy normal performance lusterless complexion, have a dizzy spell, diseases such as spiritlessness and weakness, soreness of the waist and knees, thready pulse light red tongue, mostly be prolonged illness consume, weakness of the spleen and stomach, deficiency of the liver and kindey, QI and blood scarcity, or see that apoplexy due to deficiency holds reality under the arm, have the expectorant stasis of blood concurrently, heat is long-pending etc.The spleen being the foundation of acquired constitution, the kidney being the origin of congenital constitution, the two mutual promotion, that mutually promotes is consummate theoretical, in conjunction with present-day medical knowledge, adopts spleen invigorating kidney, replenishing essence marrow, replenishing QI and blood, clear stagnant heat, Xiao mass in the abdomen is respectful evil atmosphere to set upright gas, and reasonable recipe, clinical efficacy is definite and safe and reliable.
The present invention treats the active component that the Chinese medicine preparation of digestive tract tumor comprises, and is that 8 kinds of Chinese medicine medical materials of following row weight portion proportioning are prepared from:
2～8 parts of Radix Pseudostellariaes, 1～5 part of Radix Angelicae Sinensis, 1～4 part of Ganoderma lucidum seu Japonicum, 1～4 part of Rhizoma Polygonati, 2～6 parts of Rhizoma dioscoreaes, 1～5 part of the Cortex Eucommiae, 2～8 parts of Herba Hedyotidis Diffusaes, 1～6 part of Herba Solani Lyrati.
The Chinese medicine activity of drug ingredients composition of Chinese medicine preparation of the present invention and pharmaceutical carrier are pressed arbitrary proportion and are formed, and wherein active ingredient accounts for weight ratio and can be 0.1～99.9%, and pharmaceutical carrier accounts for weight ratio can be 99.9～0.1%.Pharmaceutical carrier can be starch, dextrin, protein sugar, sucrose, micropowder silica gel, refined honey or other common carrier.
The present invention treats the Chinese medicine preparation of digestive tract tumor, has comprised the active ingredient that is prepared into by 8 kinds of Chinese medicine medical materials, because suitable compatibility has good synergism, makes this Chinese medicine preparation that better curative effect be arranged, and safe and reliable.The therapeutical effect of these components is as described below.
Radix Pseudostellariae, Radix Angelicae Sinensis: sweet flat, the merit of Radix Pseudostellariae is like Radix Ginseng and thin, the spry spleen fortune of power, gas in the drum noon.Put down in writing as Compendium of Material Medica: " control all deficiency syndrome of male woman." Radix Angelicae Sinensis and blood is enriched blood, the strong fortune of middle Jiao, then change that unboiled water paddy is precise and tiny, angerization blood, the whole body of supplementing nutrition.The same usefulness of Radix Pseudostellariae and Radix Angelicae Sinensis can strengthen the effect of benefiting QI and nourishing blood.
Ganoderma, Rhizoma Polygonati: nature and flavor are identical, and sweet flat nontoxic, only the Ganoderma speciality is protected refreshing, beneficial vital essence.Rhizoma Polygonati is then arrogated to oneself invigorating middle warmer Jiao, and settling five organs is treated all void, the replenishing essence marrow.Radix Pseudostellariae, Radix Angelicae Sinensis are joined Ganoderma, Rhizoma Polygonati in the Chinese medicine preparation, the burnt mediation in making, and QI and blood is full, mediates antitumor action to reach by raise immunity.
Rhizoma dioscoreae, the Cortex Eucommiae: vital essence in spleen invigorating kidney, bone and muscle strengthening, the kidney tonifying, fill up marrow.
Herba Hedyotidis Diffusae, Herba Solani Lyrati: heat-clearing and toxic substances removing, blood stasis dispelling removing food stagnancy, improved Chinese medicine to press down tumor and put, the attenuation synergistic of chemotherapy etc., metastasis, the effect of anti-recurrence.
All medicines match, and taste are strong, and middle Jiaoization unboiled water paddy is precise and tiny, and kidney essense is filled, and can benefit help the foundation of acquired constitution again, and QI and blood is full, and then Healthy energy reises and evil falls.Thereby improved body's immunity, promoted the good health and a long life of human body, strengthened life and life quality.
The present invention treats the modern pharmacology effect of digestive tract tumor's Chinese medicine preparation:
Experimentation proof Radix Pseudostellariae has effects such as antitumor, enhancing human body immunity function, resisting fatigue, appetite stimulator, antiallergic.
Radix Angelicae Sinensis has antitumor, corrects effects such as anemia, the liver protecting.
Ganoderma energy raise immunity has the effect of ascending peripheral white blood cells, the anti-tumor radiation function.
Rhizoma Polygonati can resist put, chemotherapeutics is to the inhibitory action of hemopoietic function of bone marrow.Experimentation proof Rhizoma Polygonati can also improve cellular immunization, promotes nucleic acid and proteinic synthetic.
Rhizoma dioscoreae, the Cortex Eucommiae have resist put, chemotherapeutics is to the inhibitory action of hemopoietic function of bone marrow.
Herba Hedyotidis Diffusae is widely used in the various oncotherapys, and anticancer, raise immunity is arranged.
Herba Solani Lyrati improved Chinese medicine to press down tumor and put, the attenuation synergistic of chemotherapy etc., metastasis, the effect of anti-recurrence.
The present invention treats digestive tract tumor's Chinese medicine preparation and can operate routinely and be prepared into granule, and its preparation method is summarized as follows:
Take by weighing each component Chinese medicine medical material by above-mentioned prescription, decoct with water secondary, decocted two hours for the first time, decocted one hour for the second time, filter, merge the secondary medicine juice, left standstill 24 hours, and got supernatant, be condensed into the thick extractum of relative density about 1.35 (80 ℃ of heat are surveyed), vacuum drying, pulverize, add an amount of pharmaceutical carrier mixing, 75% ethanol is granulated, drying, packing promptly.
The acute toxicity test of Chinese medicine preparation of the present invention:
Get 20 of healthy Kunming mouses (male and female half and half), the oral respectively medicinal liquid of having prepared of the present invention, only (be made into every milliliter with 0.5%CMC and contain 0.7 gram crude drug) by 0.8ml/, the upper and lower noon, each once gavaged, observed 14 days after the administration, the result: movable normal after the ZHIJING KELI of the oral preparation of mice, the end is seen overt toxicity reaction and dead, and growth promoter is normal.Huge inspection is dissected in off-test, and obvious pathological change is seen at the main organs end.
When the oral consumption of mice is equivalent to more than 100 times of the clinical consumption of people (people calculates with the 50kg body weight), show that this medicine is safe.
The pharmacodynamic study of Chinese medicine preparation of the present invention:
By the ZHIJING KELI pharmacodynamic study is found: ZHIJING KELI has the obvious suppression effect for murine sarcoma S180, mouse junction cancer Clon-26, human implantation's property tumor (gastric cancer) SGC; Can improve therapeutic effect with dissimilar chemotherapeutic use in conjunction, reduce chemotherapeutic toxicity; Improve the tumor-bearing mice body's immunological function; To lowering, has protective effect by the leukocyte due to the chemotherapeutic.
For this reason, we to ZHIJING KELI eliminating evil, set upright, effect aspect the potentiation, attenuation four, carried out the research of animal pharmacodynamics aspect.
1. the eliminating evil effect of ZHIJING KELI
Experiment purpose: observe the inhibitory action of ZHIJING KELI to different transplanted animal tumors
Calculate according to people's clinical dosage 10g/50kg, people's clinical dosage is 0.2g/kg.So zoopery dosage is designed to: 0.1g/kg, 0.5g/kg, three dosage groups of 2.5g/kg.
Be mixed with each dosage group with distilled water, medication is: irritate once, continuous seven times administration capacity: 0.5ml/20g every day.
1.1 ZHIJING KELI is to the inhibitory action research of murine sarcoma S180
Get well-grown murine sarcoma S180 ascites, it is subcutaneous in Kunming kind female mice one side axil to make cell suspension inoculation with normal saline by 1: 5 dilution proportion, and 0.2ml/ only.Random packet, 10 every group are established normal saline matched group, cyclophosphamide (CTX) positive drug group; ZHIJING KELI height (2.5g/kg), in (0.5g/kg), low (0.1g/kg) three dosage groups.Inoculation plays administration next day, continuous irrigation stomach 7 days, and positive drug cyclophosphamide group (100mg/kg) lumbar injection, secondary (1,4) day altogether took off neck and put to death animal in the 10th day, dissect and get the tumor piece, weigh, and were calculated as follows the result.
The results are shown in Table 1
Table 1: ZHIJING KELI is to the inhibitory action of mice S180
| Heavy (g) tumour inhibiting rate (g/kg) scheme of group dosed administration number of animals tumor is x ± sd (%) all the time |
| Blank group po * 7 10 10 2.50 ± 0.56 ZHIJING KELI, 0.1 po * 7 10 10 2.35 ± 0.95 4.08 0.5 po * 7 10 10 1.65 ± 0.34 *???29.79 ????????????2.5????????po×7??10??10??1.20±0.47 **??48.94 CTX?????????100mg/kg???ip×2??10??10??0.12±0.04 **??95.10 |
Compare with the blank group:
*P＜0.05,
*P＜0.01
As shown in Table 1: ZHIJING KELI to the tumour inhibiting rate of mice S180 when high dose (2.5g/kg) 48.94% (
*P＜0.01), during middle dosage (0.5g/kg) 29.79% (
*P＜0.05), low dosage (0.1g/kg) 4.08%.Significantly dosage correlation is arranged.
1.2 ZHIJING KELI is to the inhibitory action of F1 mouse junction cancer Clone-26
In the aseptic tumor source of taking out down, make homogenate with homogenizer, it is subcutaneous in F1 mice one side axil that the reuse normal saline is made cell suspension inoculation by 1: 4 dilution proportion, 0.2ml/.Random packet, 10 every group are established normal saline matched group, cyclophosphamide positive drug group; ZHIJING KELI height (2.5g/kg), in (0.5g/kg), low (0.1g/kg) three dosage groups.Inoculation plays administration next day, continuous irrigation stomach 7 days, and positive drug cyclophosphamide group (100mg/kg) lumbar injection, secondary (1,4) day altogether took off neck and put to death animal in the 10th day, dissect and get the tumor piece, weigh, and were calculated as follows the result.
The results are shown in Table 2
Table 2: ZHIJING KELI is to the inhibitory action of F1 mice Clone-26
| Heavy (g) tumour inhibiting rate (g/kg) scheme of group dosed administration number of animals tumor is x ± sd (%) all the time |
| Blank group Po * 7 1,010 1.98 ± 0.65 ZHIJING KELI, 0.1 Po * 7 1,010 1.44 ± 0.52 29.41 0.5 Po * 7 1,010 1.35 ± 0.41 *????31.82 ?????????????2.5??????Po×7??1010????1.23±0.40 **???37.88 CTX??????????100mg/kg?Ip×2??1010????0.32±0.13 **???83.83 |
Compare with the blank group:
*P＜0.05,
*P＜0.01
As shown in Table 2: ZHIJING KELI to the tumour inhibiting rate of mice Clone-26 when high dose (2.5g/kg) 37.88% (
*P＜0.01=, during middle dosage (0.5g/kg) 31.82% (
*P＜0.05=, low dosage (0.1g/kg) 27.27%.
1.3 ZHIJING KELI is to transplanting in the inhibitory action of the Human Gastric Cancer SGC of nude mice
In the aseptic tumor source of taking out down, make homogenate with homogenizer earlier, it is subcutaneous in the nude mice one side axil of BALB/C background that the reuse normal saline is made cell suspension inoculation by 1: 4 dilution proportion, 0.2ml/.Random packet, six every group are established normal saline matched group, cyclophosphamide positive drug group; ZHIJING KELI height (2.5g/kg), in (0.5g/kg), low (0.1g/kg) three dosage groups.Inoculation plays administration next day, continuous irrigation stomach 14 days, and positive drug cyclophosphamide group (100mg/kg) lumbar injection, totally three times (1,5,9) three days were taken off neck and are put to death animal in the 30th day, dissect and get the tumor piece, weigh, and were calculated as follows the result.
The results are shown in Table 3
Table 3: ZHIJING KELI is to the inhibitory action of Human Gastric Cancer SGC
| Heavy (g) tumour inhibiting rate (g/kg) scheme of group dosed administration number of animals tumor is x ± sd (%) all the time |
| Blank group 25ml/kg po * 14 66 1.93 ± 0.22 ZHIJING KELI, 0.1 po * 14 66 1.52 ± 0.21 19.17 0.5 po * 14 66 1.33 ± 0.24 *?????31.08 ??????????????2.5?????????po×14?6??6?????1.17±0.22 **????39.89 ??CTX?????????100mg/kg????ip×3??6??6?????0.28±0.17 **????85.49 |
Compare with the blank group:
*P＜0.01,
*P＜0.05
As shown in Table 3: ZHIJING KELI to the tumour inhibiting rate of Human Gastric Cancer SGC when high dose (2.5g/kg) 39.89% (
*P＜0.01), during middle dosage (0.5g/kg) 31.08% (
*P＜0.05), low dosage (0.1g/kg) 19.17%.
2. the potentiation of ZHIJING KELI
Experiment purpose: observe ZHIJING KELI and merge the inhibitory action of chemotherapeutic to murine sarcoma S180
According to preceding 4 experimental results ZHIJING KELI is tested dosage and be decided to be 0.4g/kg.
Medication is: irritate every day stomach once, continuous seven times, administration capacity: 0.5ml/20g.
Cyclophosphamide (CTX) test dose is designed to 20mg/kg, medication: ip * 2 (1,4).
Methotrexate (MTX) test dose is designed to 4mg/kg, medication: ip * 2 (1,4).
Mitomycin (MMC) test dose is designed to 1mg/kg, medication: ip * 2 (1,4).
Get 80 of healthy Kunming kind female mices,, after normal saline dilution in 1: 5, be inoculated in the subcutaneous 0.2ml of every mice one side axil well-grown S180 ascites.Be divided into 8 groups at random, 10 every group.(1) normal saline matched group; (2) ZHIJING KELI (0.4g/kg, po * 7 (1-7)); (3) CTX (20mg/kg, ip * 2 (1,4)); (4) MTX (4mg/kg, ip * 2 (1,4)); (5) MMC (1mg/kg, ip * 2 (1,4)); (6) ZHIJING KELI+CTX; (7) ZHIJING KELI+MTX; (8) ZHIJING KELI+MMC, dosage and dosage regimen are with individually dosed.Inoculate animal after 10 days, dissect and get the tumor piece, claim tumor heavy, calculate tumour inhibiting rate.The tumour inhibiting rate formula is:
Putting up with according to WebbShi mark product method of drug combination calculated:
(fa)
1.2＝1-[1-(fa)
1][1-(fa)
2]
(fa)
1, (fa)
2Be respectively the tumour inhibiting rate of two medicines, (fa)
1.2Be the theoretical additive effect of calculating.If the effect of drug combination is greater than theoretical additive effect, then expression is collaborative.The results are shown in Table 4.
Table 4: ZHIJING KELI merges CTX, MTX, the MMC effect to mice S180 solid tumor
| Heavy (g) tumour inhibiting rate (fa) of dosed administration number of animals tumor 1.2Merge group (mg/kg) scheme (%) effect of x ± sd (%) all the time |
| Matched group 25ml/kg po * 7 10 10 1.86 ± 0.61 (normal saline) |
| ZHIJING KELI 400 po * 7 10 10 1.47 ± 0.54 20.97 |
| ????????????????????ip×???????????????????????????1.36± CTX????????20???????????????10??10??????????????????26.88 ????????????????????2(1，4)??????????0.57 * |
| Work in coordination with+CTX 20 2 (1,4) 0.52 ZHIJING KELI 400 po * 7 ip * 10 10 1.05 ± 43.54 42.09 ** |
| ????????????????????ip×???????????????????????????1.30± MTX????????4????????????????10??10??????????????????30.64 ????????????????????2(1，4)??????????0.51 * |
| ZHIJING KELI 400 po * 7 ip * 10 10 1.0 ± 0.29 **46.23 45.10 collaborative+MTX 42 (1,4) |
| ????????????????????ip×????????????????????????????1.30± MMC????????1????????????????10??10??????????????????30.10 ????????????????????2(1，4)??????????0.38 * |
| Work in coordination with+MMC 12 (1,4) 0.29 ZHIJING KELI 400 po * 7 ip * 10 10 0.74 ± 60.21 44.70 ** |
Compare with the blank group:
*P＜0.05,
*P＜0.01
As shown in Table 4: ZHIJING KELI is at smaller dose during with different chemotherapeutic cyclophosphamide (CTX), methotrexate (MTX), mitomycin (MMC) drug combination, tumour inhibiting rate to mice S180 is 43.54%, 46.23%, 60.21%, through calculating with the Webb formula, (fa) 1.2 be respectively 42.09%, 45.10%, 44.70%, all have synergism, illustrate that ZHIJING KELI has good potentiation.
3. the Attenuation of ZHIJING KELI
Experiment purpose: the observation ZHIJING KELI acts in vain to the life of the leucocytes reduction that chemotherapeutic cyclophosphamide (CTX) causes.
Calculate according to people's clinical dosage 10g/50kg, people's clinical dosage is 0.2g/kg.So zoopery dosage is designed to: 0.1g/kg, 0.5g/kg, three dosage groups of 2.5g/kg.
Rubidate contrived experiment dosage is: 0.1g/kg.
Be mixed with each dosage group with distilled water, medication is: irritate every day stomach once, continuous seven times, administration capacity: 0.5ml/20g.
Cyclophosphamide (CTX) test dose is designed to 100mg/kg, medication: ip * 3.
With well-grown S180 ascites, after normal saline dilution in 1: 5, be inoculated in the subcutaneous 0.2ml of healthy Kunming kind female mice one side axil.Be divided into 6 groups at random, 10 of every group of mices are divided into the normal control group; CTX+ normal saline group; CTX+ Rubidate group (0.1mg/kg); CTX+ ZHIJING KELI height (2.5g/kg), in (0.5g/kg), low (0.1g/kg) three dosage groups, to inoculate day is the 0th day, CTX dosage is 100mg/kg, ip * 3 (5,6,7), ZHIJING KELI, Rubidate were po * 7d (8-4 days), at the 4th, 8,12,16,20,24 day counting leukocyte.The results are shown in Table 5
Table 5: leukopenic therapeutical effect that ZHIJING KELI causes tumor-bearing mice CTX
| ???????????????????????????????????????WBC(×10 9/ L, the group of X ± S) |
| 4d 8d 12d 16d 20d 24d normal control group 6.3 ± 1.2 10.1 ± 1.3 10.9 ± 1.6 10.1 ± 2.0 8.9 ± 1.5 11.0 ± 2.9 CTX group 7.0 ± 0.9 5.5 ± 0.5 **???4.8±0.9 **??6.9±2.0 **??7.0±1.3 **9.3 ± 0.8 CTX+ Rubidate (0.1g/kg) 5.5 ± 0.9 6.6 ± 1.2 **???13.9±2.1 **12.4 ± 3.9 9.7 ± 1.5 9.0 ± 1.9 CTX+ ZHIJING KELI (0.1g/kg) 7.1 ± 0.2 4.2 ± 0.5 **10.7 ± 3.9 10.1 ± 1.1 8.7 ± 2.3 10.7 ± 1.9 CTX+ ZHIJING KELI (0.5g/kg) 7.0 ± 0.4 4.1 ± 0.9 **11.8 ± 1.3 11.3 ± 1.9 10.3 ± 2.0 9.2 ± 0.9 CTX+ ZHIJING KELI (2.5g/kg) 6.9 ± 0.4 6.6 ± 1.2 **???12.9±1.2 **?11.7±3.0????9.7±1.5?????9.5±1.4 |
Compare with normal group:
*P＜0.05,
*P＜0.01
As shown in Table 5: tumor-bearing mice, obviously descends with normal group comparison leukocyte after 8 days at the injection cyclophosphamide.Gavage ZHIJING KELI, Rubidate group mice left and right sides leukocyte recovery in 12 days, and there do not have administration group leukocyte to rise to be slower.Wherein ZHIJING KELI high dose group recovery situation is similar to the Rubidate group, at 24 days left and right sides leukocyte all as normal.
4. ZHIJING KELI centralizing function
Experiment purpose: observe the influence of ZHIJING KELI immunity function of animal
4.1 ZHIJING KELI influences the tumor-bearing mice spleen lymphocyte proliferation
Calculate according to people's clinical dosage 10g/50kg, people's clinical dosage is 0.2g/kg.So zoopery dosage is designed to: 0.1g/kg, 0.5g/kg, three dosage groups of 2.5g/kg.
The Polysaccharide-peptide capsule test dose is designed to: 0.5g/kg
Be mixed with each dosage group with distilled water, medication is: irritate once, continuous seven times administration capacity: 0.5ml/20g every day.
Female mice axil subcutaneous vaccination Lewis lung cancer cell is about 2 * 10
6, be divided into 5 groups then at random, 6 every group.That is: ZHIJING KELI 0.1g/kg, 0.5g/kg, three dosage groups of 2.5g/kg.Polysaccharide-peptide capsule group 0.5g/kg, the normal saline matched group.All adopt po * 7d to gavage, after the last administration, put to death animal, get spleen under the aseptic condition, separating Morr. cell, counting and adjusting concentration is 1 * 10
10/ L adds 100ul cell suspension, 50ulConA, culture medium 100ul in 96 well culture plates.Each group is established 3 multiple holes, 37 ℃, 5%CO
2After cultivating 48hr under the condition, add
318hr cell harvestor collecting cell is continued to cultivate in the H-TdR18.5KBq/ hole; On liquid scintillation instrument, survey the CPM value.The results are shown in Table 6
Table 6: ZHIJING KELI is to the influence of lotus Lewis lung cancer mice spleen lymphocytes proliferation
| Group dosage (g/kg) regimen C PM value (x ± sd) |
| Matched group (normal saline) 25ml/kg po * 7 3441 ± 2473 ZHIJING KELI, 0.1 po * 7 11370 ± 5538 **??????????????????0.5???????????po×7??????8882±846 **??????????????????2.5???????????po×7??????8120±918 **Polysaccharide-peptide 0.5 po * 7 8268 ± 1438 ** |
*Compare with matched group P＜0.01
As shown in Table 6: three various dose groups of ZHIJING KELI all have facilitation to lymphopoiesis, and along with dosage increases, the lymphopoiesis effect weakens.The effect of the high dose group of ZHIJING KELI (2.5g/kg) lymphopoiesis is similar to polysaccharide-peptide.
4.2 ZHIJING KELI influences tumor-bearing mice NK cytoactive
Calculate according to people's clinical dosage 10g/50kg, people's clinical dosage is 0.2g/kg.So zoopery dosage is designed to: 0.1g/kg, 0.5g/kg, three dosage groups of 2.5g/kg.
The Polysaccharide-peptide capsule test dose is designed to: 0.5g/kg
Be mixed with each dosage group with distilled water, medication is: irritate every day stomach once, continuous seven times, administration capacity: 0.5ml/20g.
Female mice axil subcutaneous vaccination Lewis lung cancer cell is about 2 * 10
6, be divided into 5 groups then at random, 6 every group.That is: ZHIJING KELI 0.1g/kg, 0.5g/kg, three dosage groups of 2.5g/kg, Polysaccharide-peptide capsule group 0.5g/kg, normal saline matched group.All adopt po * 7d to gavage, after the last administration, put to death animal, get spleen under the aseptic condition, separating Morr. cell, counting and adjusting concentration is 1 * 10
9/ L, adding 100ul cell suspension in 96 well culture plates, adding concentration is 1 * 10
7The YAC-1 cell 100ul of/L is as target cell, adding again.
33 multiple holes, 37 ℃, 5%CO are established in H-TdR18.5KBq/ hole, each group
2After cultivating 24hr under the condition, use the cell harvestor collecting cell; On liquid scintillation instrument, survey the CPM value.Calculate specificity and suppress percentage rate (pi) expression NK cytoactive.Its computing formula:
Pi (%)=(the 1-experimental group mixes CPM value/matched group and mixes the CPM value) the results are shown in Table 7
Table 7: ZHIJING KELI is to the active influence of lotus Lewis lung cancer NK cells in mice
| Group dosage (g/kg) the regimen C PM value (PI (%) of x ± sd) |
| Matched group (normal saline) 25ml/kg po * 7 33952 ± 3558 ZHIJING KELI, 0.1 po * 7 5291 ± 582 **???75.6 ??????????????????0.5?????????po×7?????5661±2303 **??83.3 ??????????????????2.5?????????po×7?????10343±2630 **69.5 polysaccharide-peptide 0.5 po * 7 6076 ± 441 **???82.1 |
*Compare with matched group P＜0.01
As shown in Table 7: three various dose groups of ZHIJING KELI all have facilitation to the NK cytoactive, can activate the NK cell activity.0.5g/kg during dosage, its effect is similar to polysaccharide-peptide.
The present invention treats gastral Chinese medicine preparation through the clinical practice in surplus ten years, focuses on as the anti-tumor chemotherapeutic auxiliary treatment, is summarized as follows for the case clinical efficacy with gastric cancer:
Get 148 routine patients with gastric cancer at random in clinical practice, be divided into two groups, one group is that 88 examples are organized in treatment, and another group is for matched group 60 examples, situations such as two groups sex distribution, age distribution following (see Table 8 and table 9):
Table 8 liang group sex, age ratio are
| The total example man of men and women's group: woman's mean age example % example % |
| Treatment organizes 88 58 65.9 30 34.1 1.93: 1 50.6 ± 7.1 years old |
| Matched group 60 40 66.7 20 33.3 2.00: 1 50.1 ± 7.3 years old |
Table 9 liang group pathology, by stages, transfer case relatively
| Group | The clinical TNM excision in stages of pathology |
| Appeasing property of adenocarcinoma mucinous adenocarcinoma papillary adenocarcinoma signet ring cell adenocarcinoma II phase III phase IV phase radical-ability | |
| The treatment group | 54 examples, 18 examples, 10 examples, 6 examples, 52 examples, 21 examples, 13 examples, 61 examples, 16 examples |
| Matched group | 42 examples, 8 examples, 6 examples, 4 examples, 40 examples, 10 examples, 7 examples, 36 examples, 11 examples |
By table 8, table 9 as seen, two groups in sex, age, pathology, by stages, aspect equilibrium, comparable such as transfer case.
Therapeutic Method
Treatment group: ZHIJING KELI combined chemotherapy.
Chemotherapy regimen: calcium leucovorin (CF) 200mg/m
2, intravenous injection, d1～d5; With fluorouracil (5-Fu) 500mg/m
2, intravenous injection, d1～d5, chemotherapy repeated 1 cycle, totally 6 cycles in per 28 days.
Take ZHIJING KELI simultaneously, every day twice, each bag is taken June continuously.Every day, dosage contained about crude drug amount 6 grams.
Matched group: simple chemotherapy, chemotherapy regimen is identical with the treatment group with the course of treatment.
The therapeutic evaluation standard is as follows:
1) symptom variation:
Carry out the integration evaluation according to clinical traditional Chinese medical science disease standards of grading, divide clinical recovery, produce effects, effective and invalid.Clinical recovery: the symptom total mark descends 〉=95%; Produce effects: the symptom total mark descends 〉=70%; Effectively: the symptom total mark descends 〉=30%; Invalid: integration descends＜30%.
2) life quality (Karnofsky classification)
Take a turn for the better: the Karnofsky scoring increases 〉=10 fens, and keeps more than 4 weeks.Stable: the Karnofsky no significant change of marking.Progress: the Karnofsky scoring reduces 〉=10 fens, continues more than 4 weeks.
3) body weight change
Except the body weight change that causes of factor such as Celom liquid loading edema.Take a turn for the better: weight increase＞2kg, and keep more than 4 weeks.Stable: weight increase or minimizing≤2kg.Progress: lose weight＞2kg, continue more than 4 weeks.
4) lab testing:
All measure routine blood test, T cell subsets, NK cytoactive, IL-2 before and after two groups of treatments, tumor index level etc. are relatively observed.
Therapeutic outcome:
1, Syndrome in TCM marquis curative effect (seeing Table 10)
Table 10 liang group traditional Chinese medical science disease curative effect relatively
| Group example number clinical recovery produce effects enabledisable total effective rate % |
| The example number accounts for % example number and accounts for % example number and account for % example number and account for % |
| 88 8 9.09 20 22.73 32 36.36 28 31.82 68.2 matched groups 60 2 3.33 8 13.33 16 26.67 34 56.67 43.3 are organized in treatment |
Table 10 shows that treatment group total effective rate is 68.2%, and the matched group total effective rate is 43.3%.Learn by statistics for two groups and handle that there were significant differences, P＜0.05.
2, life quality scoring (seeing Table 11)
Table 11 liang group life quality scoring relatively
| Curative effect treatment group (N=88) matched group (N=60) |
| 37 examples that take a turn for the better, 10 examples are stablized 43 examples 31 example progress, 8 examples, 19 routine increase rates, 42.04% 16.66% reduced rates 9.09% 31.67% |
Table 11 shows treatment group Karnofsky scoring raising rate apparently higher than matched group, and Karnofsky scoring reduction rate is starkly lower than matched group, learns by statistics and handles, and both all have notable difference P＜0.05.
3, body weight change relatively
Treatment group body weight gain improvement rate 36.36% (32/88), coefficient of stabilization 43.18% (38/88), progression rates 20.45% (18/88).The matched group improvement rate is 13.33% (8/60), coefficient of stabilization 41.66% (25/60), progression rates 45.00% (27/60).Show that treatment group body weight gain rate is higher than matched group, difference has significant meaning P＜0.005.
4, lab index changes (seeing Table 12)
Lab index changes before and after the table 12 liang group treatment
| Index | Treatment group (N=88) matched group (N=60) |
| After treating before the preceding treatment of the treatment back treatment | |
| Hb H B (g/L) leukocyte WBC (* 10 9/ L) platelet PLT (* 10 9/L) ????CD 4/CD 8Natural killer cell NK, (%) interleukin I L-2 receptor, (%) carcinoembryonic antigen CEA, (ug/L) squamous cell carcinoma antigen CA19-9, (U/ml) cancer antigen 50 CA-50, (U/ml) | ?11.3±1.12???11.4±0.98????11.2±0.93?????11.3±0.52 ?4.3±0.4?????6.7±0.7*?????4.6±0.3???????4.0±0.8 ?188.2±21.2??190.9±22.3???167.4±18.5????147.9±20.6 ?1.2±0.5?????2.3±0.4*?????1.3±0.3???????1.1±0.5 ?16.7±9.5????20.3±8.8?????18.2±8.6??????16.5±9.1 ?5.0±1.9?????9.2±2.8*?????4.9±1.6???????4.1±2.1 ?1.8±0.3?????1.7±0.7??????1.6±0.4???????1.1±0.6 ?16.1±4.1????14.2±7.8?????12.6±3.3??????17.0±5.1 ? ?12.6±2.9????12.3±0.5?????11.8±2.3??????11.7±3.1 |
Annotate: with preceding relatively P＜0.05 of treatment.
After table 12 showed the treatment of treatment group, WBC, CD4/CD8, IL-2 expression of receptor were all than obviously improving P＜0.05 before the treatment; Other indexs no significance before and after treatment changes P＞0.05.The every index of laboratory does not all have obvious change P＞0.05 before and after the treatment of control group.
5, existence situation
The treatment group is because seriously ill dead person's 8 examples during this laboratory observation, matched group 5 examples, and because of shorter between follow-up period, no statistical significance still.
6, side reaction
Treatment is organized only 5 examples (accounting for 5.68%) clinical manifestation distension and fullness in the abdomen and loss of appetite among the 88 routine patients, matched group 60 routine patients also have 5 examples (accounting for 8.33%) clinical manifestation vomiting obviously, and diarrhea with loose stool is alleviated through anti symptom treatment, and adheres to that checking finishes.
Clinical effectiveness is summed up:
ZHIJING KELI be surplus the national famous old docter of TCM ten year over the clinical efficacy good recipe summing up, develop meticulously, look for another way.The requirement of above-mentioned experimental basis new Chinese medicine guideline focuses on and observes its safety and efficacy as the anti-tumor chemotherapeutic adjuvant, obtains the curative effect of feeling quite pleased.
1 efficacy analysis
By the comparative observation of many index before and after 148 routine patients with gastric cancer random packet and the treatment, the result shows:
(1) traditional Chinese medical science disease:
Treatment group clinical recovery accounts for 9.09%, and produce effects accounts for 22.73%, effectively accounts for 36.36%, and total effective rate reaches 68.2%;
The matched group clinical recovery accounts for 3.33%, and produce effects accounts for 13.33%, effectively accounts for 26.67%, and total effective rate reaches 43.3%.
(2) life quality (Karnosfky) scoring:
Treatment group raising rate accounts for 42.04%, and reduction rate accounts for 9.09%;
Matched group raising rate accounts for 16.66%, and reduction rate accounts for 31.67%.
(3) body weight change is relatively:
Treatment group body weight gain improvement rate accounts for 36.36%, and coefficient of stabilization accounts for 43.18%, and progression rates accounts for 20.45%;
Matched group body weight gain improvement rate accounts for 13.33%, and coefficient of stabilization accounts for 41.66%, and progression rates accounts for 45.00%.
(4) lab index changes:
Average out to 4.3 ± 0.4 * 10 before the treatment of treatment group numeration of leukocyte
9/ L is upgraded to 6.7 ± 0.7 * 10 after the treatment
9/ L;
Be 4.6 ± 0.3 * 10 before the treatment of control group
9/ L is 4.0 ± 0.8 * 10 after the treatment
9/ L.
Before the treatment of treatment group CD4/CD8 ratio is 1.2 ± 0.5, is upgraded to 2.3 ± 0.4 after the treatment; Being 1.3 ± 0.3 before the treatment of control group, is 1.1 ± 0.5 after the treatment.
Before the treatment of treatment group IL-2 receptor is 5.0 ± 1.9%, is 9.2 ± 2.8% after the treatment; Being 4.9 ± 1.6% before the treatment of control group, is 4.1 ± 2.1% after the treatment.
Conclusion:
Above-mentioned four indices shows that all treatment organizes obvious superior matched group, and difference has significant meaning P＜0.05.
2 side reactions
Viewing duration both all have few patient to occur distension and fullness in the abdomen, loss of appetite, and vomiting is obvious, and untoward reaction such as diarrhea with loose stool are alleviated through anti symptom treatment, and adhere to that checking finishes.
3 safeties
Two groups of viewing durations all have urine examined, stool routine, and hepatic and renal function etc. do not have ANOMALOUS VARIATIONS, illustrate that it is safe and reliable.
Chinese medicine preparation of the present invention is a distinguished veteran doctors of TCM in the long term medical practice, and the utilization tcm theory by the modern science detection means, develops in conjunction with abundant clinical experience.Centering, late gastric cancer patient, especially behind chemicotherapy normal performance lusterless complexion, have a dizzy spell, diseases such as spiritlessness and weakness, soreness of the waist and knees, thready pulse light red tongue, pathogenesis mostly is the prolonged illness consume, weakness of the spleen and stomach, deficiency of the liver and kindey, QI and blood scarcity, or apoplexy due to deficiency is held reality under the arm.Chinese medicine preparation of the present invention is used for the treatment of digestive tract tumor and digestive tract tumor puts, patients undergoing chemotherapy, has spleen invigorating kidney, replenishing essence marrow, replenishing QI and blood, clear stagnant heat, Xiao mass in the abdomen, sets upright the gas effect.The pharmacodynamic study of Chinese medicine preparation of the present invention also prove its have eliminating evil, set upright, potentiation, Attenuation.Clinical practice proves, this medicine safety, effective.Clinical symptoms is improved total effective rate and is reached 68.2%, and Chinese medicine preparation cooperates that the chemicotherapy treatment alleviates effectively that the cancer patient is put, the toxicity after the chemotherapy, significantly improves patient's quality of life.Cancer patient's survival rate, prolongation life span have been improved.Therefore, therapy of combining Chinese and Western medicine is the main path and the method for anti-curing oncoma from now on, and strengthening vital QI to eliminate pathogenic factors is the aim of treatment tumor.Chinese medicine preparation of the present invention is developed in line with this principle just, for market provides a kind of effective new drug, brings glad tidings to tumor patient, has very big economy and society benefit.Also press down tumor and to the attenuation synergistic of chemicotherapy for Chinese medicine, metastasis, anti-recurrence is avoided bone marrow depression and is regulated body's immunity, improves the quality of living, and prolongs life cycle, alleviates clinical symptoms, has opened up the new approaches new method.
The specific embodiment
The preparation method of embodiment 1 treatment digestive tract tumor granule
Take by weighing Herba Hedyotidis Diffusae 921g, Cortex Eucommiae (parched) 450g, Radix Pseudostellariae 350g, Rhizoma Polygonati (processed) 310g, Herba Solani Lyrati 327g, Rhizoma dioscoreae 302g, Ganoderma lucidum seu Japonicum 288g, Radix Angelicae Sinensis (parched) 252g.The about 3200g of crude drug total amount decocts with water secondary, adds 10 times of water gagings for the first time and decocts two hours, add for the second time 8 times of water gagings and decocted one hour, filter, merge the secondary medicine juice, left standstill 24 hours, and got supernatant, be condensed into the thick extractum of relative density about 1.35 (80 ℃ of heat are surveyed), vacuum drying, pulverize, add 50% dextrin mixing, 75% ethanol is granulated, drying is made 1000 gram granules.Every bag 10g contains about crude drug amount 3g.
Taking method: every day secondary, each 10 the gram, every day dosage contain crude drug about 6 the gram.
The preparation method of embodiment 2 treatment digestive tract tumor granules
Take by weighing Radix Pseudostellariae 775g, Rhizoma dioscoreae 692g, Rhizoma Polygonati (processed) 461g, Radix Angelicae Sinensis (parched) 347g, Cortex Eucommiae (parched) 347g, Herba Hedyotidis Diffusae 231g, Ganoderma lucidum seu Japonicum 231g, Herba Solani Lyrati 116g.The about 3000g of crude drug total amount decocts with water secondary, adds 10 times of water gagings for the first time and decocts two hours, add for the second time 8 times of water gagings and decocted one hour, filter, merge the secondary medicine juice, left standstill 24 hours, and got supernatant, be condensed into the thick extractum of relative density about 1.35 (80 ℃ of heat are surveyed), vacuum drying, pulverize, add 50% dextrin mixing, 75% ethanol is granulated, drying is made 1000 gram granules.Every bag 10g contains about crude drug amount 3g.
Taking method: every day secondary, each 10 the gram, every day dosage contain crude drug about 6 the gram.
The preparation method of embodiment 3 treatment digestive tract tumor granules
Take by weighing Ganoderma lucidum seu Japonicum 456g, Herba Hedyotidis Diffusae 685g, Radix Pseudostellariae 343g, Rhizoma dioscoreae 233g, Radix Angelicae Sinensis (parched) 571g, Rhizoma Polygonati (processed) 115g, Cortex Eucommiae (parched) 571g, Herba Solani Lyrati 227g.The about 3200g of crude drug total amount decocts with water secondary, adds 10 times of water gagings for the first time and decocts two hours, add for the second time 8 times of water gagings and decocted one hour, filter, merge the secondary medicine juice, left standstill 24 hours, and got supernatant, be condensed into the thick extractum of relative density about 1.35 (80 ℃ of heat are surveyed), vacuum drying, pulverize, add 50% dextrin mixing, 75% ethanol is granulated, drying is made 1000 gram granules.Every bag 10g contains about crude drug amount 3g.
Taking method: every day secondary, each 10 the gram, every day dosage contain crude drug about 6 the gram.
Embodiment 4 treatment cases
One 67 years old male patients, cause stomachache half a year, vomiting are gone to a doctor to the People's Hospital, city, are diagnosed as gastric cancer by upper digestive tract barium meal, B ultrasonic, capable immediately total gastrectomy operative treatment, pathological biopsy turns out to be adenocarcinoma of stomach.Postoperative is given chemotherapy, feels epigastric discomfort within the next few days, the sense of feeling sick, difficult feed, spiritlessness and weakness, soreness of the waist and knees.Have a medical check-up: emaciated physique, lusterless complexion, chronic facies is movable few.The visible operative incision of epigastrium, healing is good.The light red tongue thready pulse.Chemotherapy is taken Chinese medicine preparation of the present invention simultaneously, one time 1 bag, and 2 times on the one, treatment 2 week back remissions, medication are after 6 months, patient's transference cure, diet is normal, and it is good that health is recovered.
Embodiment 5 treatment cases
One 43 years old female patients epigastrium pain 6 years repeatedly are surplus, by " gastric ulcer " treatment, poor effect.The patient increases the weight of because of epigastrium pain, flatulence, feel sick, vomitted 3 days, gastroscopy is diagnosed as gastric cancer, on October 14th, 2003 to big excision of First People's Hospital, city row stomach, postoperative send pathologic finding report prompting: the lesser gastric curvature poorly differentiated adenocarcinoma, soak and placenta percreta, the placenta percreta lymph node has cancer cell metastasis for 2 pieces, began oral chemotherapeutic on October 22nd, 2003, the back sense has a delicate constitution, and loses weight, separate the urine difficulty, especially night is for very, and poor appetite, weak, symptoms such as constipation are come my institute's treatment on October 30th, 2003, give Chinese medicine preparation of the present invention, 2 times on the one, one time one bag, the conscious mental status is good after patient's medication, antisecosis, appetite increases, and defecation is normal, weight increase, after medication 3 courses of treatment, 2 months is a course of treatment, checks no abnormality seen to First People's Hospital, the immunoassay prompting: carcinoembryonic antigen is less than 0.5ng/ml, still adhere to treatment at present, appetite increases, and sleep might as well, complexion is good, weight increase, supreme abdominal pain sense, repeatedly the relapse and metastasis sign is not found in comprehensive review.
Embodiment 6 treatment cases
One 45 years old male patients touch the big lump of fist because of stomach discomfort, pain, abdominal distention and gastral cavilty portion in October, 2002, and matter is hard, and swollen thing is 6 * 13cm, through hospital gastroscope, CT examination, is diagnosed as gastric cancer.On November 23rd, 2002 capable resection of gastric carcinoma.Pathological diagnosis is to break up in the adenocarcinoma of stomach, and does 2 radiotherapy of chemotherapy 3 times.The recurrence of the residual gastropathy kitchen range of gastroscopy in July, 2003, size is 6.1 * 4.7cm, and has a stomach-ache, flatulence, feels sick, becomes thin, the whole body is weak, so can not perform the operation once more.In July, 2003 the court treatment gives Chinese medicine preparation of the present invention 2 times on the one, and one time 1 bag was taken three months, and subjective symptoms is clearly better, weight increase, antisecosis.Check on February 6th, 2004, focus is obviously dwindled, and size is 4.8 * 4.6cm.Gastroscopy on August 26 in 2004, the complete obiteration of residual stomach recurrence kitchen range, weight increase 8kg.After taking half a year, weight increase 10.5kg, antisecosis, diet is normal, can normally go to work, and health returns to be suffered from before the carninomatosis.
Embodiment 7 treatment cases
One 40 years old male patients, because of vomiting, the feed stalk of choking only advances the semi-fluid food at the beginning of calendar year 2001, and increase the weight of gradually and seek medical advice, through the prompting of upper digestive tract radiography, " the long mucosa of the about 6cm in esophagus stage casing interrupts disorder, and tube wall is stiff, expands above it ".After examining, esophagoscopy is " esophageal carcinoma ".JIUYUE in the same year anastomosis on the capable esophageal carcinoma excision of surgery, esophagus and stomach bow, postoperative pathology " esophagus squamous cell (III) phase ".My the section treatment that takes traditional Chinese medicine in November.Ordinary circumstance is relatively poor during first visit, and shape is thin, and is conscious weak, sweating, and uncomfortable in chest, anorexia is slept poor, and two just still transfer light red tongue yellow fur, thready and weak pulse.Give Chinese medicine preparation of the present invention 2 times on the one, one time 1 bag adhered to taking medicine 1 year, and patient's ordinary circumstance is good, check upper digestive tract radiography, rabat, liver function, renal function, erythrocyte sedimentation rate, carcinoembryonic antigen, immunoglobulin, complement do not have recurrence and transfer all in normal range.
Embodiment 8 treatment cases
One 70 years old female patients, because of stomachache, stool is with blood in December, 1992, and tenesmus is weak, becomes thin and seeks medical advice, and symptomatic treatment is invalid repeatedly.Take the photograph sheet and gastroscopy pathology inspection in certain hospital through the X line in August, 1993, is diagnosed as rectal adenocarcinoma, and the same year, JIUYUE was at this institute's row " radical resection of rectal carcinoma ".Pathologic examination after operation is " rectal adenocarcinoma III phase ".Postoperative is accepted therapy of combining Chinese and Western medicine, and it is surplus to be taken after mixing with liquid the moon, antisecosis, doing well,improving promptly begins chemotherapy, the MFV scheme, chemotherapeutic period is taken this Chinese medicine preparation and is alleviated toxicity, every day 2 times, each 1 bag was finished 6 chemotherapy treatments in 2 years smoothly, per 4～6 weeks of the course of treatment, its total amount is 5-fluorouracil 4～6g, mitomycin 16～24mg, vincristine 4～6mg.Continued to take medicine after 1997 3 years, half a year or 1 year are carried out comprehensive review during this, and patient's rabat, abdomen B ultrasonic, intestinal mirror, carcinoembryonic antigen, erythrocyte sedimentation rate, hepatic and renal function, immunoglobulin all belong to normal range.
Embodiment 9 treatment cases
One 37 years old female patients were suffered from carcinomaofsigmoid at the beginning of 2000 4 months, ectome and carry out chemotherapy through certain tumour hospital.Behind the first quarter moon, because of muscle power weak obviously (hemogram: hemoglobin 6.2g/L, leukocyte 1.3 * 10
9/ L), to feel sick, vomiting is to stop chemotherapy, changes my institute's treatment.See stomachache when examining, diarrhoea (day about 15 times), the whole body is weak, pale complexion, dizziness, refreshing idle, oligotrichosis is withered and yellow, and tongue is thin in vain is bored with soft pulse.Give Chinese medicine preparation secondary every day of the present invention, each 1 bag, took for 2 weeks after, stomachache alleviates, the diarrhoea number of times reduces, days 7～10 times.Stool is normal substantially after one month, day 1～2 time, be shaped, and stomachache disappears substantially, and dizzy, empty lacking taken a turn for the better, and feels sick and removes, and spirit is gradually bright.Hemogram checking: hemoglobin 10g/L, leukocyte 3.8 * 10
9/ L.Diet is cumulative, and complexion slightly take a favorable turn.After half a year, sign disappears, and two is just normal, and antisecosis is very fast, and hemogram and B ultrasonic, CT examination are all normal, sickly must cure rehabilitation.It is good that self-induction is recovered, in working work in 2002.After adhered to again continuing to take medicine 2 years, wherein again through 3 times the check, no abnormality seen.Follow up a case by regular visits to so far, rehabilitation is as usual, adheres to working work.
Claims (2)
1. Chinese medicine preparation for the treatment of digestive tract tumor, the active ingredient that it is characterized in that described Chinese medicine preparation is that 8 kinds of Chinese medicine medical materials of following row weight portion proportioning are prepared from, 2～8 parts of Radix Pseudostellariaes, 1～5 part of Radix Angelicae Sinensis, 1～4 part of Ganoderma lucidum seu Japonicum, 1～4 part of Rhizoma Polygonati, 2～6 parts of Rhizoma dioscoreaes, 1～5 part of the Cortex Eucommiae, 1～6 part of 2～8 parts of Herba Hedyotidis Diffusaes and Herba Solani Lyrati.
2. Chinese medicine preparation according to claim 1 is characterized in that described Chinese medicine preparation is a granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510025151 CN1284587C (en) | 2005-04-18 | 2005-04-18 | Preparation of Chinese traditional medicine for treating trmor in alimentary canal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510025151 CN1284587C (en) | 2005-04-18 | 2005-04-18 | Preparation of Chinese traditional medicine for treating trmor in alimentary canal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1695731A true CN1695731A (en) | 2005-11-16 |
| CN1284587C CN1284587C (en) | 2006-11-15 |
Family
ID=35348720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510025151 Expired - Fee Related CN1284587C (en) | 2005-04-18 | 2005-04-18 | Preparation of Chinese traditional medicine for treating trmor in alimentary canal |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1284587C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352525A (en) * | 2014-10-15 | 2015-02-18 | 磐安县道地磐药中药研究所 | Freeze-dried goose blood powder for preventing and treating gastrointestinal tumors as well as preparation method and application thereof |
| CN104352803A (en) * | 2014-10-31 | 2015-02-18 | 夏征梅 | Traditional Chinese medicinal preparation for treating stomach cancer |
| CN107375815A (en) * | 2017-07-31 | 2017-11-24 | 新乡医学院第附属医院 | A kind of Chinese medicine for treating tumor in digestive tract |
| CN108175816A (en) * | 2018-01-31 | 2018-06-19 | 黄河科技学院 | A kind of Chinese medicine for promoting apoptosis of tumor cells and preparation method thereof |
| CN108261534A (en) * | 2018-01-31 | 2018-07-10 | 黄河科技学院 | A kind of Chinese medicine that tumour knurl is promoted to wither away and preparation method thereof |
| CN114404490A (en) * | 2022-03-31 | 2022-04-29 | 江西纤仁本草堂生物科技有限公司 | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method thereof |
-
2005
- 2005-04-18 CN CN 200510025151 patent/CN1284587C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352525A (en) * | 2014-10-15 | 2015-02-18 | 磐安县道地磐药中药研究所 | Freeze-dried goose blood powder for preventing and treating gastrointestinal tumors as well as preparation method and application thereof |
| CN104352803A (en) * | 2014-10-31 | 2015-02-18 | 夏征梅 | Traditional Chinese medicinal preparation for treating stomach cancer |
| CN107375815A (en) * | 2017-07-31 | 2017-11-24 | 新乡医学院第附属医院 | A kind of Chinese medicine for treating tumor in digestive tract |
| CN108175816A (en) * | 2018-01-31 | 2018-06-19 | 黄河科技学院 | A kind of Chinese medicine for promoting apoptosis of tumor cells and preparation method thereof |
| CN108261534A (en) * | 2018-01-31 | 2018-07-10 | 黄河科技学院 | A kind of Chinese medicine that tumour knurl is promoted to wither away and preparation method thereof |
| CN114404490A (en) * | 2022-03-31 | 2022-04-29 | 江西纤仁本草堂生物科技有限公司 | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method thereof |
| CN114404490B (en) * | 2022-03-31 | 2022-11-04 | 江西纤仁本草堂生物科技有限公司 | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1284587C (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1284587C (en) | Preparation of Chinese traditional medicine for treating trmor in alimentary canal | |
| CN100337662C (en) | Medicinal composition for treating hyperlipemia and its preparing method | |
| CN1203872C (en) | Medicine for curing chronic colitis | |
| CN1245189C (en) | Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis | |
| CN1833695A (en) | Tonifying speen and tonifying kidney granular and its prepn. method | |
| CN101036741A (en) | Medicine for treating cancer and preparing method therefor | |
| CN1883640A (en) | Medicine for treating leucocytopenia caused after tumor radiotherapy and chemotherapy | |
| CN1323687C (en) | Blood supplementing iron supplementing medicineal preparation and its preparation method | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1931346A (en) | Anticancer soft capsule and its prepn process | |
| CN1698818A (en) | Medicine for treating chronic stomach disease and its preparation method | |
| CN1162177C (en) | Medicine for curing fatty liver | |
| CN1207030C (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN1211110C (en) | Chinese medicine composition for treating tumour | |
| CN1250273C (en) | Venom capsule for treating brain cancer | |
| CN101062374A (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1931314A (en) | Medicine and its prepn process | |
| CN1524552A (en) | Chinese medicine preparation for treating fatty liver | |
| CN1092972C (en) | Medicine for resisting tumor and carcinomatosis | |
| CN1323679C (en) | Medicine for treating enteron diseases | |
| CN1285365C (en) | Combination of Chinese traditional medicine in use for assistant treating cancer and preparation method | |
| CN1562114A (en) | Medicine for treating chronic prostatitis and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI FANGXIN HEALTH SCIENCE AND TECHNOLOGY DEV Free format text: FORMER OWNER: SHANGHAI FANGXIN TECHNOLOGY INSTITUTE Effective date: 20101125 Owner name: SHANGHAI FANGXIN TECHNOLOGY INSTITUTE |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200032 ROOM 888, NO.1755, XIETU ROAD, SHANGHAI TO: 200032 ROOM C, 13/F, NO.69, MEDICAL COLLEGE ROAD, XUHUI DISTRICT, SHANGHAI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101125 Address after: 200032 room 13, building 69, road, Xuhui District Medical College, Shanghai, Co-patentee after: SHANGHAI FANGXIN TECHNOLOGY INSTITUTE Patentee after: SHANGHAI FANGXIN HEALTH TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 200032 Shanghai Xietu Road No. 1755 room 888 Patentee before: Shanghai Fangxin Technology Institute |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 201203 Shanghai Zhangjiang hi tech Park Cailun Road, room 716 No. 780 Patentee after: SHANGHAI FANGXIN HEALTH TECHNOLOGY DEVELOPMENT Co.,Ltd. Patentee after: SHANGHAI FANGXIN TECHNOLOGY INSTITUTE Address before: 200032 room 13, building 69, road, Xuhui District Medical College, Shanghai, Patentee before: SHANGHAI FANGXIN HEALTH TECHNOLOGY DEVELOPMENT Co.,Ltd. Patentee before: Shanghai Fangxin Technology Institute |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20160216 Address after: 201203 Shanghai Zhangjiang hi tech Park Cailun Road, room 716 No. 780 Patentee after: SHANGHAI FANGXIN HEALTH TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 201203 Shanghai Zhangjiang hi tech Park Cailun Road, room 716 No. 780 Patentee before: SHANGHAI FANGXIN HEALTH TECHNOLOGY DEVELOPMENT Co.,Ltd. Patentee before: Shanghai Fangxin Technology Institute |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061115 Termination date: 20180418 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |